Affinity Investment Advisors Lowers stake in Boston Scientific Corporation (BSX)

Boston Scientific Corporation (BSX) : Affinity Investment Advisors reduced its stake in Boston Scientific Corporation by 0.14% during the most recent quarter end. The investment management company now holds a total of 1,052,768 shares of Boston Scientific Corporation which is valued at $23.5 Million after selling 1,432 shares in Boston Scientific Corporation , the firm said in a disclosure report filed with the SEC on May 12, 2016.Boston Scientific Corporation makes up approximately 2.09% of Affinity Investment Advisors’s portfolio.

Other Hedge Funds, Including , Canada Pension Plan Investment Board reduced its stake in BSX by selling 938,000 shares or 90.19% in the most recent quarter. The Hedge Fund company now holds 102,060 shares of BSX which is valued at $2.3 Million. Boston Scientific Corporation makes up approx 0.01% of Canada Pension Plan Investment Board’s portfolio.Advisor Partners boosted its stake in BSX in the latest quarter, The investment management firm added 1,031 additional shares and now holds a total of 17,441 shares of Boston Scientific Corporation which is valued at $389,806. Boston Scientific Corporation makes up approx 0.15% of Advisor Partners’s portfolio. Pacad Investment Ltd. added BSX to its portfolio by purchasing 14,076 company shares during the most recent quarter which is valued at $310,094. Boston Scientific Corporation makes up approx 0.04% of Pacad Investment Ltd.’s portfolio.

Boston Scientific Corporation opened for trading at $22.29 and hit $22.52 on the upside on Friday, eventually ending the session at $22.37, with a gain of 0.90% or 0.2 points. The heightened volatility saw the trading volume jump to 85,33,288 shares. Company has a market cap of $30,353 M.

On the company’s financial health, Boston Scientific Corporation reported $0.28 EPS for the quarter, beating the analyst consensus estimate by $ 0.04 according to the earnings call on Apr 27, 2016. Analyst had a consensus of $0.24. The company had revenue of $1964.00 million for the quarter, compared to analysts expectations of $1912.86 million. The company’s revenue was up 11.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.21 EPS.

Many Wall Street Analysts have commented on Boston Scientific Corporation. Company shares were Reiterated by RBC Capital Mkts on Apr 28, 2016 to “Outperform”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Stifel on Apr 28, 2016 to “Buy”, Firm has raised the Price Target to $ 25 from a previous price target of $22 .Company shares were Reiterated by Wedbush on Apr 28, 2016 to “Neutral”, Firm has raised the Price Target to $ 23 from a previous price target of $19 .

Boston Scientific Corporation develops manufactures and markets medical devices. The Company offers its products by seven core businesses: Interventional Cardiology which includes Drug-Eluting Coronary Stent Systems Intravascular Imaging devised and Coronary Technology products such as guide wires guide catheters and balloon catheters among others; Peripheral Interventions (PI) which include stents balloon catheters wires peripheral embolization devices and vena cava filters; Cardiac Rhythm Management (CRM) which include implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities; Electrophysiology (EP) which include steerable RF ablation catheters intracardiac ultrasound catheters diagnostic catheters delivery sheaths and other accessories; Endoscopy which includes Spyglass System WallFlex Colonic Stents Resolution Clip and Expect Aspiration Needle among others; Urology and Women’s Health and Neuromodulation.

Leave a Reply

Boston Scientific Corporation - Is it time to Sell?

Top Brokerage Firms are advising their investors on Boston Scientific Corporation. Subscribe to MoneyFlowIndex.Org Pre-Market Alerts, You will be the first to know the street buzz.